When is Pfizer releasing its Q2 2025 earnings?

Pfizer is releasing its Q2 2025 earnings on August 5, 2025, before the U.S. market opens. Analysts are anticipating an EPS of $0.57 with revenue at $13.53 billion.

What are analysts' ratings for Pfizer?

Analysts currently have a 'Hold' rating on Pfizer with a consensus score of 3.00, indicating a stable outlook amidst the current market conditions. The price targets range from a low of $24.00 to a high of $34.00.

What is Pfizer's expected revenue growth?

Pfizer's expected revenue growth for Q2 2025 is approximately 8.77%, reflecting strong demand across its pharmaceutical product lines and strategic market positioning.

How is Pfizer managing its profit margins?

Pfizer's profit management involves a gross profit margin of 67.39% and an operating profit margin of 23.65%, indicative of effective cost control and operational efficiency.

What role does Meyka play in investment analysis?

Meyka provides real-time stock market insights and predictive analytics, enabling data-driven investment decisions. It's a useful tool for investors tracking stocks like Pfizer.

Global Market Insights

Pfizer’s Q2 2025 Earnings: A Closer Look at Revenue and Profit Margins

ByHuzaifa Zahoor August 5, 2025August 5, 2025

On August 5, 2025, Pfizer is releasing its highly anticipated Q2 2025 financial results. Analysts expect earnings of $0.57 per share and revenue reaching $13.53 billion. This report spotlights Pfizer’s financial health, revealing insights into its revenue streams and evolving profit margins amidst shifting market dynamics. Let’s delve into how Pfizer’s performance is shaping investor expectations, especially concerning its vast pharmaceutical portfolio.